SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 16, 2014
(Exact name of registrant as specified in
|(State of other jurisdiction
|(Commission File Number)
Barents Sea Circle, Lake Forest, California 92630
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (949) 470-2300
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 16, 2014, the
Board of Directors (the “Board”) of Cryoport, Inc. (the “Company”) elected Ramkumar Mandalam, Ph.D. to
Dr. Mandalam, who is
49 years old, is the President and CEO of Cellerant Therapeutics, Inc., a clinical stage biotechnology company developing novel
cell-based and antibody therapies for cancer treatment and blood-related disorders. Prior to joining Cellerant in 2005, he was
the Executive Director of Product Development at Geron Corporation, a biopharmaceutical company where he managed the development
and manufacturing of cell based therapies for treatment of degenerative diseases and cancer. From 1994 to 2000, he held various
positions in research and development at Aastrom Biosciences, where he was responsible for programs involving ex vivo expansion
of human bone marrow stem cells and dendritic cells.
Dr. Mandalam received
his Ph.D. in Chemical Engineering from the University of Michigan, Ann Arbor, Michigan. Dr. Mandalam is the author or co-author
of several publications, patent applications, and abstracts.
The Board concluded
that Dr. Mandalam should serve as a director on our Board in light of his knowledge and experience within the biotechnology and
There have been no
related party transactions between the Company and Dr. Mandalam, and there were no arrangements or understandings between Dr. Mandalam
and any other person pursuant to which he was selected as director.
Dr. Mandalam is not
a party to and does not currently participate in any material Company plan, contract or arrangement. As non-employee director,
he will participate in the Company’s director compensation plan governed by the Compensation Committee and will receive an
initial grant to purchase 100,000 shares of the Company’s common stock upon joining the Board. In addition, Dr. Mandalam
will receive cash compensation as a non-employee director in the amount of $40,000 annually.
He will also be a member
of the Company’s Compensation Committee and the Company’s Nomination and Governance Committee.
copy of the press release announcing Dr. Mandalam’s appointment is attached to this Current Report on Form 8-K as Exhibit
99.1 and is incorporated herein by this reference.
|Item 9.01||Financial Statements and Exhibits
|(d)||Exhibits. The following material is filed as an exhibit to this
Current Report on Form 8-K:
|99.1||Press Release, dated June 16, 2014.
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|Date: June 16, 2014
||/s/ Robert Stefanovich
||Chief Financial Officer
Press Release, dated June 16, 2014, issued by the Registrant.